Posted by Michael Wonder on 20 Oct 2023
FDA grants fast track designation to ANPD001, autologous investigational cell therapy for the treatment of Parkinson's disease
19 October 2023 - Aspen Neuroscience today announced that the US FDA has granted fast track designation for ANPD001 for the treatment of Parkinson's disease to improve motor function.
ANPD001, is a personalised (autologous) cell therapy under investigation to treat Parkinson's disease by replacing lost dopamine neurons.
